Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Piramal Pharma's Total Operating Expense for the
three
months ended in Jun. 2026 was ₹14,460 Mil. Piramal Pharma's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹56,559 Mil.
Piramal Pharma Total Operating Expense Related Terms
Piramal Pharma Total Operating Expense Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's Total Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piramal Pharma Total Operating Expense Calculation
Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.
Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹56,559 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Operating Expense of ₹56,559 Mil mean?
Piramal Pharma (NSE:PPLPHARMA) has a Total Operating Expense of ₹56,559 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Piramal Pharma and its competitors.
Is Piramal Pharma's Total Operating Expense too high?
Piramal Pharma's current Total Operating Expense is ₹56,559 Mil. Overall, Piramal Pharma has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Total Operating Expense compare to ZTS?
Piramal Pharma's Total Operating Expense of ₹56,559 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Piramal Pharma and its competitors. Piramal Pharma's current Total Operating Expense is ₹56,559 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹176.52, compared to a current price of ₹195.68 — trading 10.9% above its estimated fair value. The current Total Operating Expense is ₹56,559 Mil. Piramal Pharma's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Total Operating Expense is ₹56,559 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹195.68 is trading 10.9% above its estimated GF Value™ of ₹176.52.
GuruFocus considers Piramal Pharma to be Modestly Overvalued.
Key valuation signals for NSE:PPLPHARMA:
Total Operating Expense: ₹56,559 Mil
GF Value™: ₹176.52 vs. price of ₹195.68 (10.9% above fair value)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
50GF Score
Get the complete analysis for NSE:PPLPHARMA
Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
